Publication: Effect of zidovudine treatment in late pregancy on HIV-1 in utero transmission
Issued Date
1997-08-01
Resource Type
ISSN
00048666
Other identifier(s)
2-s2.0-0030806793
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Australian and New Zealand Journal of Obstetrics and Gynaecology. Vol.37, No.3 (1997), 329-331
Suggested Citation
Surasak Taneepanichskul, Sayomporn Sirinavin, Winit Phuapradit, Kamhaeng Chaturachinda Effect of zidovudine treatment in late pregancy on HIV-1 in utero transmission. Australian and New Zealand Journal of Obstetrics and Gynaecology. Vol.37, No.3 (1997), 329-331. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/18106
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Effect of zidovudine treatment in late pregancy on HIV-1 in utero transmission
Other Contributor(s)
Abstract
In Thailand, the prevalence of paediatric HIV-1 infection has increased rapidly through vertical transmission. According to the ACTG 076 trial regimen, zidovudine treatment in HIV-infected pregnancy can reduce vertical transmission. However, this treatment is complex and costly. It is not applicable for developing countries. We conducted a study to evaluate the effect of zidovudine treatment in late pregnancy on HIV-1 in utero transmission. Fifty cases of asymptomatic HIV-1 infected-women were voluntarily enrolled to the study. Zidovudine 250 mg orally twice a day was given to these patients from gestational age 36 weeks until labour. The newborns were evaluated at birth by a neonatologist and peripheral blood was tested for HIV genome by PCR technique within 48 hours of birth. The study revealed that no HIV genome was detected from the peripheral blood of newborns. It is suggested that zidovudine treatment in late pregnancy could reduce HIV-1 in utero transmission.